Branch Retinal Vein Occlusion
Conditions
Keywords
ranibizumab, PRN regimen, macular edema, branch retinal vein occlusion
Brief summary
Monthly intravitreal ranibizumab (IVR) during the first 6 month had great effect for macular edema with branch retinal vein occlusion (BVO) both in visual and anatomical outcome. It is expected that similar results could be obtained by less frequent IVR. The purpose of this study is to investigate if IVR by PRN is as effective as by monthly. In addition, the investigators are going to study the relationship between macular edema and the size and location of retinal non-perfusion area.
Detailed description
It was demonstrated in BRAVO study that IVR had great effect for macular edema with BVO both in visual and anatomical outcome. However IVR was done monthly for all patients (except Sham group) during the first 6 months in BRAVO study. It is expected that similar results could be obtained by less frequent IVR, and if so, it will contribute to reduce patient's burden and medical cost. Thus it is necessary to determine the optimal regimen of IVR therapy. In this study, considering the medical and social circumstances in Japan, the investigators are going to investigate if IVR by PRN is as effective as BRAVO study.In addition, the investigators are going to study the relationship between macular edema and the size and location of retinal non-perfusion area (NPA), because VEGF is thought to be released from non-perfused retinal tissue, and VEGF production may be correlated with NPA size and location. The investigators are going to measure the size of NPA semi-quantatively by ultra wide field fluorescein angiography (UWFA) using Optos 200Tx. Then the relationship with macular edema will be studied. The effect of ranibizumab to NPA is controversial. In this study, it will be investigated, too.
Interventions
DRUGRanibizumab
Intraviteal injection of 0.5mg ranibizumab
Sponsors
Novartis
Nagoya City University
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
50 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Signed informed consent form * Macula edema secondary to BRVO * BCVA of 77 to 20 letters assessed with the use of ETDRS charts * CRT ≧250μm
Exclusion criteria
* Previous treatment with anti-VEGF drugs or corticosteroid or grid laser photocoagulation (study eye) * History of vitrectomy surgery, submacular surgery, or other surgical intervention for RVO * Ocular disorders in the study eye that may confound interpretation of study results * BCVA over 77 letters between screening and Day 0 * The pregnant or lactating woman
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Visual acuity | One years |
Secondary
| Measure | Time frame |
|---|---|
| central foveal thickness | One and two years |
| Visual acuity | Two years |
Other
| Measure | Time frame |
|---|---|
| size and location of retinal non-perfusion area | one and two years |
Countries
Japan
Outcome results
None listed